The Swedish biotech company has entered into a research collaboration agreement with Eli Lilly and Company to apply its AbiProt technology to generate antibodies against a well-validated target protein.
This partnership aims to accelerate research and development of innovative treatments and, if successful, will generate milestone payments and royalty income, states the company.
Under the terms of the agreement, Oblique will collaborate with Lilly Catalyze360-ExploR&D, an external innovation arm of Eli Lilly and Company that brings business knowledge, scientific expertise and research and development to accelerate the partner’s scientific work.
This collaboration with Lilly is of great importance to us and will further strengthen our position in the discovery of new antibody-based drugs.”
The collaborators already have an existing agreement (signed in November 2023), and this agreement extends the collaboration between the companies to a second well-validated target protein.
“We are extremely excited to expand the collaboration between our companies and together create new science to meet the medical need in critical diseases. This collaboration with Lilly is of great importance to us and will further strengthen our position in the discovery of new antibody-based drugs,” says Christer Nordstedt, CEO of Oblique Therapeutics.
Photo: iStock
